Greenfield, Indiana, USA. (Wednesday, 27 January 2016) – Today at Elanco Animal Health, a subsidiary of Eli Lilly & Co. (LLY), we informed our workforce in Sligo, Ireland that we have made the decision to close our Sligo manufacturing facility.
The difficult decision was reached as part of an in-depth evaluation of our global manufacturing operations. The global evaluation has also resulted in the decision to exit ownership of our manufacturing operations in Dundee, Scotland.
Unfortunately, cost reduction initiatives at Sligo, including a restructuring last year, have not been sufficient in establishing a competitive business model for the facility. Approximately 100 employees will be made redundant at the Sligo manufacturing site. We anticipate the majority of employees will leave the facility early in the second quarter of 2016. A small number of employees will support product transfer and decommissioning activities throughout 2016 and into 2017.
A consultation phase will commence in early February to help employees understand the closure plans and examine options available to them. Elanco is fully committed to supporting employees throughout this process. We will provide regular updates and support to all employees, including working closely with other Elanco European sites, as well as other Lilly-owned entities in Ireland, to identify potential employment opportunities. Elanco will provide comprehensive outplacement support for impacted employees.
“The decision to close the Sligo facility is difficult, and we are very aware of the impact this has on our employees, their families, and the local region,” said Grace McArdle, Site Manager, Elanco Sligo. “Over the next few weeks, our priority will be communicating with our employees and providing support at this difficult time.”
These business decisions were made after evaluating operations across Elanco’s global manufacturing network, and are not a reflection of site performance at Sligo. The changes, while difficult, are aligned with Elanco’s objectives to maintain a competitive advantage in the continually changing animal health business.
Elanco Animal Health is a division of Eli Lilly & Company, a global healthcare company. Elanco’s decision to close the Sligo manufacturing site has no impact on other Lilly- owned entities in Ireland.
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.
About Eli Lilly and Company Entities in Ireland
Lilly has had a presence in Ireland for over 35 years with approximately 1,000 employees in multiple locations. The Lilly Global Business Solutions Centre, established in 2010, employs about 350 multi-discipline, multi-lingual employees in Cork. Approximately, 600 employees are located at the company’s active pharmaceutical ingredient manufacturing site in Kinsale, Cork. To date, Lilly has invested €1.3 billion into the Kinsale facility. The site is currently constructing a €330 million biotech facility which will come on line in 2017. In addition, Kinsale has commenced a €40 million investment in new technology for the manufacturing of active pharmaceutical products.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. F-LLY